Anti-DLL3-Anti-CD3 Bispecific Molecule

• Background:

  DLL3, also known as delta like ligand three, is a Notch ligand characterized by a DSL domain, transmembrane region, and a series of EGF repeats. Notch ligands can participate in trans-interactions (interaction with Notch receptor on a different cell) and cis interactions (interaction with Notch receptor within the same cell) to activate or inhibit Notch signaling, respectively. DLL3 exclusively functions to inhibit Notch signaling through cis inhibition. While DLL3 expression is limited in healthy tissue, high expression levels of DLL3 are found in various cancers including small cell lung cancer (SCLC), where it plays an oncogenic role. Relieving DLL3-mediated inhibition of Notch signaling may serve as a therapeutic avenue, with drugs being developed to target DLL3 as a possible lung cancer therapy (example: rovalpituzumab tesirine) .

• Description:

  Anti-DLL3-Anti-CD3 Bispecific Molecule is a purified recombinant human bispecific molecule with T cell Engager. This bispecific molecule has been tested for specific activity in a functional reporter assay using NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #60621) co-cultured with DLL3 CHO Cell Line (BPS Bioscience #78882) .

• UniProt:

  DLL3: Q9NYJ7

• Applications:

  The Anti-DLL3-Anti-CD3 Bispecific Molecule can be used for studying DLL3+cancer cell-mediated T cell activation, using either primary T cells or reporter cell lines such NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #60621) .

• Purity:

  ≥ 90%

• Format:

  Aqueous buffer solution.

• Shipping Conditions:

  -80°C

• Storage Conditions:

  At least 12 months at -80°C.

• Calculated Molecular Weight:

  105 kDa + glycans

• Formulation:

  8 mM phosphate, pH 7.4,110 mM NaCl, 2.2 mM KCl, and 20% glycerol

• Glycosylation:

  This molecule runs at a higher MW by SDS-PAGE due to glycosylation.